ArticleAmerican journal of physiology. Lung cellular and molecular physiology2023
Metabolic profiling of in vivo right ventricular function and exercise performance in pulmonary arterial hypertension.
Open access · hybridAbstract read
In one paragraph
Article in American journal of physiology. Lung cellular and molecular physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Metabolomics in Pulmonary Hypertension-A Useful Tool to Provide Insights into the Dark Side of a Tricky Pathology.International journal of molecular sciences · 2023Pooled it
- Cardiometabolic reprogramming in pulmonary arterial hypertension: Implications for right ventricular dysfunction and therapeutic strategies.Chinese herbal medicines · 2026Review
- Metabolic Markers as Potential Risk Factors in Pulmonary Hypertension.Pulmonary circulation · 2026Article
- Divergent Inflammatory and Bioenergetic Metabolomic Signatures Distinguish Methamphetamine-Associated From Idiopathic Pulmonary Arterial Hypertension.Pulmonary circulation · 2026Article
- Metabolomic Network Analysis Reveals Reorganization of Lipid and Steroid Programs Linked to Right Ventricular-Pulmonary Vascular Function in Pulmonary Hypertension.bioRxiv : the preprint server for biology · 2026Article
- The tryptophan-kynurenine pathway in cardiovascular diseases: mechanistic insights and therapeutic opportunities.Frontiers in cardiovascular medicine · 2026Review
- Pathophysiology of Pulmonary Arterial Hypertension: Focus on Vascular Endothelium as a Potential Therapeutic Target.International journal of molecular sciences · 2025Review
- Bioenergetics and metabolism of the pulmonary endothelium. Scientific session I: ReSPIRE 2025.American journal of physiology. Lung cellular and molecular physiology · 2025Review
- Metabolic Alterations Associated With Right Ventricular Dysfunction in Pulmonary Arterial Hypertension: The Modulatory Effects and Improvement Mechanisms of Exercise.Reviews in cardiovascular medicine · 2025Review
- Dysregulated Tricarboxylic Acid Cycle Metabolism Is Associated With Right Ventricular Maladaptation in Pulmonary Vascular Disease.Journal of the American Heart Association · 2025Observational
- Dysregulation of Mitochondrial in Pulmonary Hypertension-Related Right Ventricular Remodeling: Pathophysiological Features and Targeting Drugs.Reviews in cardiovascular medicine · 2025Review
- Alterations in Mitochondrial Function in Pulmonary Vascular Diseases.Antioxidants & redox signaling · 2025Article
- Exercise Pulmonary Hypertension and Beyond: Insights in Exercise Pathophysiology in Pulmonary Arterial Hypertension (PAH) from Invasive Cardiopulmonary Exercise Testing.Journal of clinical medicine · 2025Review
- IDO-Dependent Tryptophan Metabolites and Endocan as Effective Diagnostic Biomarkers for Pregnancy with Pulmonary Hypertension.International journal of women's health · 2025Article
- Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series).Pulmonary circulation · 2025Article
- Circulating biomarkers in pulmonary arterial hypertension: State-of-the-art review and future directions.JHLT open · 2024Review
- Perturbations of tryptophan catabolism via the kynurenine pathway are associated with stage 2 postoperative outcomes in single ventricle heart disease.Physiological reports · 2024Article
- Aberrant long-chain fatty acid metabolism associated with evolving systemic sclerosis-associated pulmonary arterial hypertension.American journal of physiology. Lung cellular and molecular physiology · 2024Observational
- Low global arginine bioavailability: a common phenomenon in pulmonary hypertension.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Editorial: Pulmonary hypertension: from bench to bedside.Frontiers in physiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Catherine E SimpsonDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.ORCID 0000-0002-2388-5660
Julie CoursenDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Steven HsuDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Ethan K GoughDivision of Human Nutrition, Johns Hopkins University School of Public Health, Baltimore, Maryland, United States.
Robert HarlanMolecular Determinants Core, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States.
Aurelie RouxMolecular Determinants Core, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States.ORCID 0000-0001-5579-001X
Susan AjaMolecular Determinants Core, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States.
David GrahamMolecular Determinants Core, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States.
Matthew KauffmanDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Karthik SureshDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.ORCID 0000-0003-2920-0949
Ryan J TedfordDivision of Cardiology, Medical University of South Carolina, Charleston, South Carolina, United States.
Todd M KolbDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.ORCID 0000-0003-0524-7400
Stephen C MathaiDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Paul M HassounDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.ORCID 0000-0003-0601-4975
Rachel L DamicoDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Johns Hopkins University · USMedical University of South Carolina · US
Funding
Mechanisms of Right Ventricular Dysfunction in Scleroderma-associated PAHR01HL114910 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M. · 2012 to 2023
$6.2MFunctional Impact of Col18a1/Endostatin Variants in PAHR01HL132153 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI DAMICO, RACHEL L, HASSOUN, PAUL M. · 2017 to 2020
$2.5MMetabolic regulation of Ca2+ entry and endothelial-mesenchymal transition in pulmonary arterial hypertensionR01HL151530 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SURESH, KARTHIK · 2021 to 2025
$2.0MHopkins Clinical Center for Pulmonary Vascular Disease Phenomics ProgramU01HL125175 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M., MATHAI, STEPHEN C · 2015 to 2019
$1.1MMechanisms and treatment of right ventricular sarcomere dysfunction in scleroderma-associated pulmonary arterial hypertensionK23HL146889 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HSU, STEVEN · 2019 to 2023
$886kThe role of xanthine oxidoreductase activity and altered metabolism in scleroderma-associated pulmonary arterial hypertensionK23HL153781 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SIMPSON, CATHERINE · 2020 to 2024
$883kROS-induced endothelial dysfunction in pulmonary arterial hypertensionK08HL132055 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SURESH, KARTHIK · 2017 to 2021
$828kNHLBI NIH HHS K08 HL132055NHLBI NIH HHS K23 HL146889NHLBI NIH HHS K23 HL153781NHLBI NIH HHS R01 HL114910NHLBI NIH HHS R01 HL132153NHLBI NIH HHS R01 HL151530NHLBI NIH HHS U01 HL125175
Abstract
Right ventricular (RV) adaptation is the principal determinant of outcomes in pulmonary arterial hypertension (PAH), however, RV function is challenging to assess. RV responses to hemodynamic stressors are particularly difficult to interrogate without invasive testing. This study sought to identify metabolomic markers of in vivo right ventricular function and exercise performance in PAH. Consecutive subjects with PAH (
Indexed as
Pulmonary Arterial HypertensionVentricular Dysfunction, RightArginineBiomarkersFamilial Primary Pulmonary HypertensionHumansKynurenineNatriuretic Peptide, BrainVentricular Function, RightArginineBiomarkersKynurenineNatriuretic Peptide, Brainmetabolismpulmonary hypertensionright ventricle
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.